Navigation Links
PRoFESS(R) Results Announced at XVII European Stroke Conference
Date:5/14/2008

RIDGEFIELD, Conn., May 14 /PRNewswire/ -- Results of the PRoFESS(R) (Prevention Regimen For Effectively avoiding Second Strokes) trial -- the world's largest clinical research study for secondary stroke prevention -- were presented today at the XVII European Stroke Conference in Nice, France. In the study, recurrent stroke event rates for Aggrenox(R) and clopidogrel were similar (9.0% and 8.8%, respectively; HR 1.01, 95% CI 0.92-1.11). The study did not meet its primary endpoint of non-inferiority for AGGRENOX versus clopidogrel.(1)

In further exploratory analysis of the main secondary endpoint of the composite of stroke, myocardial infarction or vascular death, AGGRENOX and clopidogrel showed similar outcomes (13.1% versus 13.1%).(1)

In PRoFESS, the AGGRENOX arm had a higher number of hemorrhagic strokes compared to clopidogrel (0.8% and 0.4%, respectively) while ischemic stroke recurrences were less frequent in the AGGRENOX arm compared to the clopidogrel arm (7.7% and 7.9%, respectively).(1)

A post-hoc analysis showed comparable numbers of death and disabling strokes and a similar neurological outcome as measured by the modified Rankin Scale(2) at three months after the recurrent stroke and at the end of the PRoFESS trial between the two treatment arms.(1)

Major hemorrhagic events were observed more frequently in the AGGRENOX group compared with clopidogrel (4.1% versus 3.6%; HR 1.15, 95% CI 1.00-1.32). The benefit-risk ratio expressed as the combination of recurrent stroke and major hemorrhage was not significantly different between AGGRENOX and clopidogrel (11.7% and 11.4% respectively; HR 1.03, 95% CI 0.95-1.11).(1)

"Given the high prevalence of stroke and recurrent stroke in aging societies, physicians need a range of treatment options so they can offer patients a regimen tailored to their individual needs," said Professor Hans-Christoph Diener, MD, University of Essen, Germany, one of the three principal investigator
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
2. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
3. Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile
4. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
5. DATATRAK International Reports First Quarter Results for 2008
6. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
7. Exelixis Announces First Quarter 2008 Financial Results
8. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery
9. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
10. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
11. Senetek PLC Announces Positive Results from Pyratine-6(TM) Clinical Trial in Patients with Acne Rosacea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014  VentiRx Pharmaceuticals, Inc., a clinical ... and commercialization of novel Toll-like receptor 8 ... Food and Drug Administration (FDA) has granted ... motolimod (VTX-2337) when administered in combination with ... of women with ovarian cancer whose disease ...
(Date:9/2/2014)...   Intrexon Corporation (NYSE: XON ... it has entered into an Exclusive Channel Collaboration (ECC) ... (EURONEXT: SAN and NYSE: SNY ) to ... of its marketed Active Pharmaceutical Ingredients (APIs) through Sanofi,s ... This collaboration will leverage Intrexon,s proprietary technology suite plus ...
(Date:9/2/2014)... , Sept. 2, 2014   Veracyte, Inc. (Nasdaq: ... Anderson , president and chief executive officer, will present in ... Healthcare Unplugged Conference 2014 on Monday, September 8, 2014 at ... The live audio webcast and subsequent replay may ... Please connect to the website at least 15 minutes prior ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 2VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 3Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 2Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 3Veracyte to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2014 2
... YORK, Sept. 1, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0559262/Global-CRO-Market-Quantitative-Assessment.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development This ... globally, by phase and market type, R&D ...
... This evening, Novo Nordisk awarded sponsorships totaling ... that educate people living with type 2 diabetes on ... risk of long-term diabetes related complications. The sponsorships are ... aims to promote enduring, sustainable change for people living ...
Cached Medicine Technology:Global CRO Market: Quantitative Assessment 2Global CRO Market: Quantitative Assessment 3Novo Nordisk Partners with Minneapolis Community Groups to Support Diabetes Education Programs 2
(Date:9/2/2014)... 02, 2014 West Hollywood cosmetic ... consultations for Invisalign. This special offer includes a free ... to determine their candidacy for the procedure and answer ... patients may also be eligible for the Summer Invisalign ... of the month of August, patients who choose Invisalign ...
(Date:9/2/2014)... MONDAY, Sept. 1, 2014 (HealthDay News) -- The quality ... overall, and dietary disparity between the rich and poor ... provides the most direct evidence to date that the ... U.S. dietary quality are having some payoff, but it ... study author Dong Wang, a doctoral student in the ...
(Date:9/2/2014)... 2, 2014 (HealthDay News) -- When it comes to excess ... equal, a new study finds. The research found that ... person,s odds for high blood pressure more than overall body ... of high blood pressure. But it wasn,t clear how the ... to researchers at University of Texas Southwestern Medical Center in ...
(Date:9/2/2014)... Dallas, Texas (PRWEB) September 02, 2014 ... , “North America Resectoscopes Market Outlook to 2020? ... Resectoscopes market. The report provides value, in millions ... prices (in US dollars) within market segments –, ... Electrodes (Monopolar (Disposable and Reusable) Electrodes and Bipolar ...
(Date:9/2/2014)... USARAD Holdings Inc. a leading ... provider, including SecondOpinions.com® – consumer division is gaining ... services. The telemedicine industry pioneer is now partnering ... Founded and established in 1963 as the first ... as a maternity care hospital with very few ...
Breaking Medicine News(10 mins):Health News:West Hollywood Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Complimentary Consultations for Invisalign 2Health News:Quality of U.S. Diet Improves, Slightly 2Health News:'Spare Tire' May Be Especially Bad for Your Blood Pressure 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 3Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 4Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 2Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 3Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 4
... blockbuster drug and greater reimbursement levels for the treatment ... smoking cessation and addiction treatments are expected to ... 2005 to more than $2.3 billion in 2010, according ... Analysis, a new study released today from Kalorama Information. ...
... a computer based test that may reveal how easily an ... that her scientific test can be used as another ... in fields where employee distraction can lead to fatal errors. ... liable to do things like put your keys in the ...
... are hopeful that the actress' current rehab spell will bring ... wacky recent incidents . ,As the Mean Girls ... on May 28, after being arrested for DUI, her supposed ... ,One friend told America's Star magazine that Lohan ...
... of Illinois dentists provide oral cancer examinations for their ... thoroughly or at optimum intervals, according to a new ... of pre-malignant lesions and of proper examination techniques, some ... be doing to detect oral cancers in their patients," ...
... on Thursday announced that FDA has granted a standard ... Cervarix, Reuters reports. A GSK spokesperson on Thursday said ... been completed in six months. ,Cervarix and ... 100% effective in preventing infection with HPV strains 16 ...
... Dey, L.P. announced today that the U.S. Food ... Drug Application (NDA) of its marketing partner, Critical ... tablets. ZYFLO CR(TM) offers twice-daily, extended-release dosing. Under ... in March 2007, DEY will co-market Critical Therapeutics' ...
Cached Medicine News:Health News:Individuals Distraction can Be Measured by a Computer Based Test 2Health News:Dentists Need More Training in Oral Cancer Detection 2Health News:Dentists Need More Training in Oral Cancer Detection 3Health News:FDA Approves ZYFLO CR(TM) (Zileuton) for Chronic Treatment of Asthma 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: